New approach aims to tame immune storms in Half-Matched transplants
NCT ID NCT06828796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immune-suppressing drug tacrolimus earlier than usual can lower the risk of cytokine release syndrome (CRS), a severe inflammatory reaction, in patients receiving a half-matched stem cell transplant for blood cancer. About 20 adults will receive the modified drug schedule. The goal is to make the transplant safer while still controlling the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASE AND DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Could End-of-Life care for blood cancer patients be done at home?